Physician profile
Alan C Yao
NPI 1053325647
$50,663.45
in general payments reported to CMS, 2019-2025
12 companies · $3,988 in 2025
The $3,988 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $3,824 · 2021: $7,661 · 2022: $6,456 · 2023: $3,250 · 2024: $7,158 · 2025: $3,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $1,781 · Education: $45.04 · Travel and Lodging: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,530.00 |
| Food and Beverage | $1,781.07 |
| Education | $45.04 |
| Travel and Lodging | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $49,331.01 | 2019-2025 | Vemlidy |
| Intra-Sana Laboratories | $491.78 | 2022-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Abbvie INC. | $194.99 | 2019-2021 | |
| Insmed, INC. | $125.00 | 2019 | |
| Amgen INC. | $120.04 | 2019 | |
| Lilly USA, LLC | $109.19 | 2025 | Kisunla |
| Janssen Pharmaceuticals, INC | $103.37 | 2019 | |
| Celltrion USA INC. | $99.28 | 2024-2025 | Zymfentra, Vegzelma |
| Iridex Corporation | $38.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.64 | 2024 | Entyvio |
| Capsovision, INC. | $16.21 | 2024 | Capsocam Plus |
| Pfizer INC. | $13.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Yao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.